Dr James Brenton
Cancer Research UK Cambridge Institute
Cancer Services, Cambridge University Hospitals
University of Cambridge
Senior Group Leader
Ovarian cancer has a disproportionately high health care burden because of low cure rates and frequent symptoms caused by recurrent bulky abdominal disease after primary therapy. The fundamental clinical problem remains the acquisition of drug resistance, and studies on clinical samples to identify common mechanisms are of the utmost importance to improve treatment and survival.
Our approach to identifying critical pathways in resistance has been to develop novel phase II clinical trials with sequential collection and profiling of ovarian cancer tissues before and during therapy. Array-based expression profiling and bioinformatic analysis has identified misregulated extracellular matrix proteins in association with resistance. Array comparative genomic hybridisation is also being used to identify copy number changes associated with chemoresistance.